Human blood serum of cancer, cancer-recovered and healthy patients contains laevorotatory and dextrorotatory B2 active molecules. The laevorotatory B2 active carriers in patient serum carry information on the cancer s...Human blood serum of cancer, cancer-recovered and healthy patients contains laevorotatory and dextrorotatory B2 active molecules. The laevorotatory B2 active carriers in patient serum carry information on the cancer status while the dextrorotatory B2 active carriers carry information on the recovered and/or healthy patient status. Their magneto-optical characteristic is analysed by the B2 Magneto Optical Circular Birefringence. By applying the MOCB experimental technique, it is possible to differentiate between the cancer and non-cancer patients. The paper introduces a purely molecular physics approach for description of the cancer/recovered and also non-cancer patients status.展开更多
On the basis of the results of magneto-optical studies and their comparison with the outcome of medical tests magneto-optical MOCB and tPSA serum markers of cancer/recovered patient are presented. Status of the cancer...On the basis of the results of magneto-optical studies and their comparison with the outcome of medical tests magneto-optical MOCB and tPSA serum markers of cancer/recovered patient are presented. Status of the cancer serum donor is recognized as presence of the laevorotatory optical active molecules of (-)p density in serum while status of the recovered donor is recognized as quantitative domination of the dextrorotatory (+)p molecules in serum. These molecular information carriers (-)p and (+)p are recorded by the magneto-optical circular birefringence MOCB effect in B2 magnetic field. The laevo/dextrorotatory carriers are enantiomers in the case of (-)p = (+)p relations fulfilled for any individual cancer and the same recovered patient. The positive predictive value PPV of MOCB results is 100%.展开更多
Molecular structure of the marker of tumour is determined by magneto-optical analysis of blood serum. The marker is the laevorotatory enantiomer of alanine. The cancer status of a subject is described by the number of...Molecular structure of the marker of tumour is determined by magneto-optical analysis of blood serum. The marker is the laevorotatory enantiomer of alanine. The cancer status of a subject is described by the number of molecules of the laevorotatory alanine enantiomer <sup>(-)</sup>ρ and the effectiveness of therapy is measured by the number of molecules of the dextrorotatory alanine enantiomer <sup>(+)</sup>ρ. The values of <sup>(-</sup><sup>)</sup>ρ and <sup>(+)</sup>ρ are determined separately for the patient before and after therapy.展开更多
文摘Human blood serum of cancer, cancer-recovered and healthy patients contains laevorotatory and dextrorotatory B2 active molecules. The laevorotatory B2 active carriers in patient serum carry information on the cancer status while the dextrorotatory B2 active carriers carry information on the recovered and/or healthy patient status. Their magneto-optical characteristic is analysed by the B2 Magneto Optical Circular Birefringence. By applying the MOCB experimental technique, it is possible to differentiate between the cancer and non-cancer patients. The paper introduces a purely molecular physics approach for description of the cancer/recovered and also non-cancer patients status.
文摘On the basis of the results of magneto-optical studies and their comparison with the outcome of medical tests magneto-optical MOCB and tPSA serum markers of cancer/recovered patient are presented. Status of the cancer serum donor is recognized as presence of the laevorotatory optical active molecules of (-)p density in serum while status of the recovered donor is recognized as quantitative domination of the dextrorotatory (+)p molecules in serum. These molecular information carriers (-)p and (+)p are recorded by the magneto-optical circular birefringence MOCB effect in B2 magnetic field. The laevo/dextrorotatory carriers are enantiomers in the case of (-)p = (+)p relations fulfilled for any individual cancer and the same recovered patient. The positive predictive value PPV of MOCB results is 100%.
文摘Molecular structure of the marker of tumour is determined by magneto-optical analysis of blood serum. The marker is the laevorotatory enantiomer of alanine. The cancer status of a subject is described by the number of molecules of the laevorotatory alanine enantiomer <sup>(-)</sup>ρ and the effectiveness of therapy is measured by the number of molecules of the dextrorotatory alanine enantiomer <sup>(+)</sup>ρ. The values of <sup>(-</sup><sup>)</sup>ρ and <sup>(+)</sup>ρ are determined separately for the patient before and after therapy.
